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Abstract
Background: Bioinformatics research for finding biological mechanisms can be done by analysis of transcriptome
data with pathway based interpretation. Therefore, researchers have tried to develop tools to analyze transcriptome
data with pathway based interpretation. Over the years, the amount of omics data has become huge, e.g., TCGA, and
the data types to be analyzed have come in many varieties, including mutations, copy number variations, and
transcriptome. We also need to consider a complex relationship with regulators of genes, particularly Transcription
Factors(TF). However, there has not been a system for pathway based exploration and analysis of TCGA multi-omics
data. In this reason, We have developed a web based system BRCA-Pathway to fulfill the need for pathway based
analysis of TCGA multi-omics data.
Results: BRCA-Pathway is a structured integration and visual exploration system of TCGA breast cancer data on
KEGG pathways. For data integration, a relational database is designed and used to integrate multi-omics data of
TCGA-BRCA, KEGG pathway data, Hallmark gene sets, transcription factors, driver genes, and PAM50 subtypes. For
data exploration, multi-omics data such as SNV, CNV and gene expression can be visualized simultaneously in KEGG
pathway maps, together with transcription factors-target genes (TF-TG) correlation and relationships among cancer
driver genes. In addition, ’Pathways summary’ and ’Oncoprint’ with mutual exclusivity sort can be generated
dynamically with a request by the user. Data in BRCA-Pathway can be downloaded by REST API for further analysis.
Conclusions: BRCA-Pathway helps researchers navigate omics data towards potentially important genes, regulators,
and discover complex patterns involving mutations, CNV, and gene expression data of various patient groups in the
biological pathway context. In addition, mutually exclusive genomic alteration patterns in a specific pathway can be
generated. BRCA-Pathway can provide an integrative perspective on the breast cancer omics data, which can help
researchers discover new insights on the biological mechanisms of breast cancer.
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Background
Transcriptome data measured at the whole genome level
requires interpretation at a higher level. For this rea-
son, biological pathway analysis of transcriptome data
has become a standard approach, e.g., Pathview [1],
Pathway Inspector [2]. However, existing pathway based
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analysis tools are not powerful enough for the analysis of
omics data from cancer, a complex disease that requires
integrated analysis of multi-omics data. For example,
single nucleotide variation (SNV) and copy number vari-
ation (CNV) are frequently measured for cancer research.
Thus, it is necessary to integrate and analyze multi-omics
datasets of different types together. A number of tools,
including TCGA2STAT [3], have been developed for
TCGA multi-omics analysis. However, these tools require
experienced programming abilities and knowledge about
the detailed specification of TCGA data. Meanwhile, there
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exist web-based multi-omics data analysis services, such
as cBioPortal [4], OASIS [5], NetGestalt [6]. These frame-
works provide easy access and interpretation of multi-
omics data. OASIS provides multi-omics data such as
mutation, CNV, and gene expression in selected cancer
types and selected oncogenic pathways. However, multi-
omics data is presented in a table format, so there is no
information about the relationship between genes. Net-
Gestalt provides network-centric view of multi-omics data
by adopting visualization on the horizontal dimension to
scale up to large networks. In addition, by zooming into a
specific gene, multi-omics data of each gene is shown and
protein-protein interactions around the selected gene are
provided. KeyPathwayMinerWeb provides online multi-
omics network enrichment analysis. From user provided
gene expression data and an active gene list, maximally
connected subnetworks using PPI are provided. These
systems display the relationship of genes on the network
but do not present multi-omics data on the network. On
the contrary, our system, BRCA-Pathway, is designed to
represent relationship between genes and corresponding
multi-omics data simultaneously on the KEGG pathways.
In summary, pathway based multi-omics analysis system
is necessary but challenging due to larger sample sizes and
higher dimension (multi-omics). For these reasons, we
developed BRCA-Pathway, a web-based interactive explo-
ration and visualization system of TCGA breast cancer
data on KEGG pathways to provide broad perspective of
TCGA breast cancer data. The major features are:
• Multi-omics data such as SNV, CNV, and gene
expression can be visualized simultaneously on KEGG
pathway maps, together with TF-TG correlation and
relationships among cancer driver genes.
• Users can perform comparative analysis of BRCA
data, including selection of differentially expressed
genes (DEGs) in arbitrary patient groups, mutual
exclusivity module (MEMo) summary of genomic
alterations (SNV and CNV).
• Data can be downloaded by REpresentational State




BRCA-Pathway consists of three components: Database
system, REST API, and Web front-end. Overall system
design is described in Fig. 1. BRCA-Pathway integrates
multiple resources in a relational database and pro-
vides a web-based interactive interface and REST API. A
database system using MySQL is designed for the struc-
tural integration of multi-omics data of TCGA-BRCA,
KEGG pathway data, Hallmark gene sets, TF-TG relation-
ships, driver genes, and PAM50 subtype. BRCA-Pathway
system can update KEGG Pathways and TCGA-BRCA
data by initiating the update software module to incor-
porate the most recent information. Current configura-
tion is based on KEGG Pathway released on October 1,
2016 and the latest version of GDAC Firehose on
January 28, 2016.
Data sources
BRCA-Pathway stores and utilizes data such as TCGA
breast cancer data, breast cancer subtype by PAM50, TF-
TG regulation data, Hallmark gene sets, driver gene list
and KEGG pathway data. Data is accessible by web-server
system or REST API. Data source and status is described
in the Table 1.
TCGA breast cancer multi-omics data
TCGA breast cancer data was obtained from FIREHOSE
[7]. Clinical data was obtained from ‘Clinical_Pick_Tier1’.
In addition to clinical data common to all cancer types,
breast cancer specific features were selected and stored
in BRCA-Pathway system. Additional features are ER,
PR, HER2 receptor status and menopause status. Three
hormone receptors have been used as the marker of
the breast cancer sub-typing [8]. Also, late menopause
at age over 55 is known as an risk factor of breast
cancer [9]. Gene expression data was obtained from
‘illuminahiseq_rnaseqv2-RSEM_genes_normalized’. Each
breast cancer patient has 20,531 gene-level RNA-seq
expression data (RSEM normalized counts) from their
tumor samples. About 10% of the patient have gene
expression data from their normal samples. We used
gene expression data from patient wide normal sam-
ples as the normal pool data, and gene expression data
from patient wide tumor samples as the tumor pool data
for the comparison and visualization of gene expres-
sion data from selected sub-population. Mutation data
was obtained from ‘Mutation_Packager_Oncotated_Calls’.
The mutation table includes mutated gene ID, and
detailed information about the mutation. Because the
patterns of mutation in oncogenes are nonrandom and
characteristic, and also because oncogenes are recur-
rently mutated at the same amino acid positions [10], we
included detailed information such as ‘genome_change’
field describing the chromosomal position. CNV data was
obtained from ‘CopyNumber Gistic2’.
Breast cancer subtype data
Breast cancers are classified into subtypes based on gene
expression data. PAM50 breast cancer subtyping is widely
used method to classify breast cancer into four subtype:
Luminal A, Luminal B, Basal-like, HER2-enriched. Breast
cancer subtype data is generated using PAM50 predictor
bioclassifier R script [11]. The gene expression value of
each of PAM50 genes was log2-transformed before the
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Fig. 1 System design for BRCA-Pathway. BRCA-Pathway system structure overview. The left part is client side, and the right part is BRCA-Pathway
server side. BRCA-Pathway server builds the database which contains structured TCGA multi-omics data and KEGG pathway data. Database is
abstracted by virtual view which simplifies table join functions. REST API could get the data set when it throws query to database. These data set will
be provided by Django framework so that the clients can access the data set by web browser or terminal. BRCA-Pathway web front-end receives the
data set and visualizes for clients
PAM50 run. Users can select the patient group by subtype
and TCGA clinical information.
KEGG pathway data
BRCA-Pathway stored KEGG pathway data by access-
ing KEGG API [12] and KEGG PATHWAY Database
[13]. Gene information such as gene names, KEGG IDs,
and relations between pathways and genes was obtained
from KEGG REST API [14]. Information about graphi-
cal representations of pathway was acquired from KEGG
PATHWAY Database [15].
TF-TG regulation data
KEGG pathway includes information about the gene-
gene relation (activation, suppression, gene-gene inter-
action, etc.). However, relationships between TFs and
potential target genes are not provided by the KEGG
pathway. To supplement the KEGG pathway, we pro-
vide Pearson correlation coefficient between TF-TG with
the KEGG pathway. TF-TG relationships were obtained
from two different databases. Molecular Signatures
Database provides gene sets that share a transcription
factor binding site defined in TRANSFAC database [16].
Human Transcriptional Regulation Interaction Database
(HTRIdb) is a database for experimentally verified human
transcriptional regulation interactions [17]. The union
set of both databases are stored in BRCA-Pathway
TF-TG table.
Hallmark gene sets
Hallmark gene sets summarize and represent well-
defined biological states or processes and display coherent
expression. Fifty Hallmark gene sets were obtained from
MSigDB [18]. When researchers are interested in specific
biological process, they can start to explore TCGA data by
selecting Hallmark gene sets.
Driver gene list
Driver gene is a gene that contains driver gene muta-
tions or is expressed aberrantly in a fashion that confers a
selective growth advantage [10]. We obtained driver gene
list consisting of oncogenes and Tumor Suppressor Genes
(TSG) from Cancer Gene Census in COSMIC database
[19] and the previous research [10]. BRCA-Pathway rep-
resents driver genes on the pathway.
BRCA-Pathway workflow
In order to start with BRCA-Pathway, users need to
select pathways of their interest. There are several ways
to select pathways (Fig. 2). First, users select path-
ways by differentially expressed genes (DEGs). Users
select patient sub-population by PAM50 subtype and
clinical information, then BRCA-Pathway starts to per-
form a Wilcoxon rank-sum test for two groups, i.e.,
selected sub-population as case and 112 normal sam-
ples or remaining rest tumor samples as control. As a
result, DEGs and KEGG pathways including DEGs are
listed. For example, when users want to explore ‘Basal-
like’ subtype patients and select the condition for DEG
computation, BRCA-Pathway returns the pathway list
including DEGs in ‘Basal-like’ subtype compared with
either normal samples or the rest breast tumor samples.
After selecting pathways and loading TCGA data, BRCA-
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Table 1 Description of data provided by BRCA-Pathway: data
type, data size, and data source
Data type Data size Data source
Clinical 1098 patients Standardized analysis-ready TCGA
22 attributes data,
1098 rows Broad Institute TCGA genome
Expression 1093 patients data analysis center (2016):
20,531 genes Firehose stddata__2016_01_28
22,440,383 rows run. Broad Institute of MIT and
Mutation 977 patients Harvard.
17,280 genes doi:10.7908/C11G0KM9
86,765 rows
CNV 1080 patients Broad Institute TCGA genome
24,776 genes data analysis center (2016):
26,758,080 rows SNP6 copy number analysis
(GISTIC2). Broad Institute of
MIT and Harvard.
doi:10.7908/C1NP23RQ











50 Hallmark gene sets Molecular signatures database
(MSigDB)
Driver genes 486 driver genes Cancer gene census in COSMIC
database
Vogelstein, Bert, et al. “Cancer
genome landscapes.” science
339.6127 (2013): 1546-1558. Table
S2A
Pathway will show gene-expression, CNV and mutation
data mapped on selected pathways. Second, users select
pathways from Hallmark gene sets. When a hallmark gene
set is selected, BRCA-Pathway shows the list of related
KEGG pathways by the number of included genes in
the selected hallmark gene set. In the same way, users
are provided KEGG pathway list by submitting gene
symbols.
Pathway-based exploration of TCGA BRCA
BRCA data can be explored in different ways. For exam-
ple, when users specify subpopulation of TCGA breast
cancer patients, the system loads multi-omics data of the
selected subpopulation into the web-browser. By clicking
‘Data overlap option’, users can change the type of data
(gene expression, mutation and CNV) mapped onto the
pathway. This enables users to see the same pathway by
three different points of view. BRCA-Pathway colorizes
KEGG Pathway entries according to the user-controllable
classification criteria. The system provides a function that
highlights specific patterns of omics data such as gene
expression level up, mutation free and copy number dele-
tion (Fig. 3). In addition, ‘Pathways summary’ and ‘Onco-
print’ are available. Pathways summary is shown in Venn
diagram [20] that shows overlapped genes among selected
multiple pathways (Fig. 4). Genomic alterations such as
mutation and CNV in the same pathway are often mutu-
ally exclusive [21] and different combination of alterations
are sufficient to perturb the pathways [22]. Thus, predict-
ing driver alterations from the frequency of occurrence
is not easy. With pathway leveled view, overall trend of
genomic alteration is shown, but mutually exclusive pat-
terns of alteration are not recognizable. To compensate
this problem, we provide OncoPrint [23] with ‘mutual
Fig. 2 Example workflow of BRCA-Pathway. There are several ways to select KEGG pathways. In this example, pathway selection by DEG is described.
First, select subpopulation by breast cancer subtype and clinical features (a). If patients with ‘Basal-like’ subtype are selected, then pathways
including differentially expressed genes are listed as the result of computation of Wilcoxon rank-sum test (b). Select pathways from the list then
BRCA-Pathway visualizes multi-omics data of patients whose subtype is ‘Basal-like’. Users can view the pathway by three different data types. Gene
expression, mutation, and CNV data are visualized in separate way or integrated way. Genes having specific omics-pattern are highlighted by
selecting the omics condition. For example, genes having no mutation and of which CNV is loss or del but overexpressed are selected for
highlighting then the pathway turns shaded except the highlighted genes (c)
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Fig. 3 TCGA BRCA multi-omics data exploration with BRCA-Pathway. Visualization of TCGA BRCA with BRCA-Pathway (a) Multi-omics data of
patients whose subtypes are ‘Basal-like’ is mapped on hsa04110 (Cell cycle). Users can view pathway maps in three different data types. Gene
expression, mutation and CNV data are visualized either separately or integrated. Genes with specific patterns are highlighted by selecting the
conditions. For example, genes, having no mutation and of which CNV is loss or del but that are over-expressed, are selected. Genes in the pathway
except the highlighted genes become shaded (b) Clicking a gene entry on the pathway displays multi-omics data of the gene such as gene
expression level compared with normal sample pool and with tumor sample pool, mutation count and ratio, CNV as -2 (del), -1 (loss), 0 (neutral), 1
(gain), 2 (amp) with the count of patients having each CNV value and Pearson correlation coefficients of TF-TG gene expression. Three columns
represent the correlation of TF-TG in normal sample pool, tumor sample pool and selected subpopulations pool, respectively. Correlation with
p-value over 0.05 are shaded. c Selecting genes, Oncoprint shows copy number variation (amp or del) and mutation in the mutual exclusive way
between selected genes. In this case, some extremely over-expressed genes (fold change>10 by normal sample pool) and RB1 are selected and the
figure shows mutual exclusive pattern between CCNE2, RB1, CCNE1 and CDKN2A (top 4 rows respectively)
exclusivity sort’. Users can check on mutual exclusivity
in selected patient group with respect to CNV and
mutation.
Figure 3a shows a pathway leveled view of ‘Basal-like’
subtype patients and Fig. 3b shows the individual omics
data of CCNA1, CCNA2. The highlighted genes are muta-
tion free, copy number loss or deletion enriched but
over-expressed compared to normal pool data. Because
mutation effects are excluded, there probably exist regula-
tors that promoted the transcription of CCNA1, CCNA2.
With provided TF-TG correlation coefficient, users get
TF list targeting CCNA1, CCNA2 and see that the corre-
lation coefficients are different between normal samples
and selected tumor samples.
User data visualization on KEGG pathways
BRCA-Pathway provides visualization of user data to
extend the usability of the system. After switching to ‘User
data mode’, input a text file consisting of Entrez geneId
and fold change value, and the gene expression level is
shown in color. Adjusting color or threshold value helps to
customize pathway visualization. However, unlike ‘TCGA
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Fig. 4 Venn diagram for Pathways summary. Pathway relations are shown in Venn diagram. A list of pathways and the number of genes in each
pathway are described on the right side. Genes shared between pathways are listed under the Venn diagram
mode’, only a single gene selected by the entry label is con-
sidered and all the other genes belonging to the entry are
ignored.
REST API
REST API separates data extraction from the develop-
mental environment so that users can easily extract data
without understanding the internal system [24]. Given
patient selection option in the web page, a front-end pro-
gram creates a URL and sends the URL to REST API. This
allows the system to aggregate omics data sets for a subset
of patients to create a dynamic user view. By using REST
API, it is possible to extract genes contained in KEGG
pathway maps and to aggregate TCGA data after receiving
query result from MySQL. Users can access to data with
simple endpoint coding.
The domain address is the server URL that BRCA-
Pathway is configured on. After the slash(/) mark, at
least one argument should be given. The 1st argu-
ment specifies the data to retrieve and the argument
can be landscape, search, genes, pathways,
TCGA-BRCA. In case of tcga-brca.bhi2.snu.ac.
kr/api/landscape, ‘landscape’ represents the cur-
rent status of TCGA data and KEGG pathway. ‘search’
means that the pathway list will be provided by search-
ing gene names or pathway names, and ‘genes’ pro-
vides the gene list in pathways specified by argument 2.
Furthermore, ‘pathways’ returns pathway information
specified by argument 3’s endpoint filtered by argu-
ment 2. REST API examples are listed below. The last
example means that it will provide the result of aggre-
gating CNV data from TCGA-BRCA data given the
patients option is male and the genes filtered by the










Patient_options are listed below:
• subtype_BHI_RNASeq_Log2 :
all|Basal|Her2|LumA|LumB|Normal
• years_to_birth_from : integer & years_to_birth_to :
integer
• er_status : all|indeterminate|negative|positive
• pr_status : all|indeterminate|negative|positive
• her2_status :
all|indeterminate|negative|positive|equivocal




• pathologic_T_stage : all|t1|t2|t3|t4|tx
• pathologic_N_stage : all|n0|n1|n2|n3|nx
• pathologic_M_stage : all|cm0_|m0|m1|mx
• gender : all|female|male







• number_of_lymph_nodes : all|0|1|2 *1: #of node less
than or equal to 10, 2: greater thane 10
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Table 2 REST API arguments and parameters supported by BRCA-Pathway
arg1 arg2 arg3 Parameters Description
landscape - - type=[JSON | LIST]
fields=[KEGGPathway_update
| KEGGPathways
| Pathway_Pathway_Membership KEGG pathways, TCGA-
| TCGAGenes BRCA data status
| TCGA_BRCA_Patients
| TCGA_BRCA_update
| TFTG_relation | driver_genes]
search - - keyword
type=[ JSON | LIST ] Get search result by
fields=[ keyword keyword.
| gene_labels Gene or pathway names
| rate with input_type.
| pathID | pathname ]
genes (pathIDs, - type=[ JSON | LIST ]
sep=“+”) count fields=[ pathID Retrieve pathways
| gene_symbol information.
| pathname related_pathways operation
| geneID supported.
| count** ]
**given only arg3 related_pathways
pathways (pathIDs, - type=[ JSON | LIST ]
sep=“+”) related_pathways fields=[ pathID | pathname Retrieve pathways
| category_level2_id information.
| description related_pathways operation
| related_pathID**] supported.
**given only arg3 related_pathways
TCGA-BRCA patient_list - type=[ JSON | LIST ]
patient_count - ** arg2 patient_list
(pathIDs, (given pathIDs,) fields=[patient_barcode] Retrieve pathways and
sep=“+”) fold_change TCGA-BRCA omics data.
mutation ** arg2 patient_count Gene expression with
CNV fields=[count] fold_change value,
mutation with the number
** arg3 fold_change of patients having
fields=[geneID|gene_symbol mutation, and CNV with
| exp_select GISTIC2 result range from
| exp_tumor -2 to 2.
| exp_normal Each omics result will be
| fc_select_tumor| fc_select_normal ] given by gene level
aggregating patients
group omics data
** arg3 mutation patient_list,
fields=[ geneID | gene_symbol patient_count operation
|count ] supported.
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Table 2 REST API arguments and parameters supported by BRCA-Pathway (Continued)













• menopause_status : all|indeterminate|peri|post|pre
Discussions
Survival analysis
BRCA-Pathway provides survival analysis of selected
patients. It divides the selected patients into two groups
according to the presence of mutation in genes belong to
a particular pathway and provides survival analysis for the
patient population. For example, if user selected ‘Basal’
subtype and ‘Cell cycle’ pathway then patients of ‘Basal’
subtype are divided into two groups, mutation group and
mutation free group. Patients having at least one mutation
in the genes involved in the ‘Cell cycle’ pathway belong to
the mutation group. On the other hand, patients without
a mutation in ‘Cell cycle’ pathway belong to the mutation
free group. Two hundred twenty-eight patients of ‘Basal’
subtype are divided into mutation group (168 patients)
and mutation free group (60 patients). The green and red
line represent the survival curves of mutation group and
mutation free group, respectively. P-value by the logrank
test is provided for the comparison of two groups, and
all breast cancer patients are depicted as blue line for the
convenience. Figure 5a gives a p-value of 0.05, which indi-
cates a significant difference between the survival curves.
Figure 5b gives a p-value of 0.02, the survival curve of
‘Her2’ patients having mutation in ‘Oocyte meiosis’ and
‘Her2’ patients having no mutation in ‘Oocyte meiosis’
pathway.
Gene prioritization
If the user wants to prioritize genes that is significant
in ‘Basal’ subtype breast cancer, the exploration can start
from DEGs in ‘Basal’ subtype. By selecting patient sub-
population as ‘Basal’ and comparison condition as normal
pool, then DEGs and related pathways are shown. Since
the ‘Cell cycle’ pathway is listed at the top rank, it is natu-
ral to select and load ‘Cell cycle’ pathway for the next step.
Fig. 5 Survival analysis. a ‘Basal’ subtype and ‘Cell cycle’ pathway are selected, patients with at least one mutation in the genes involved in the ‘Cell
cycle pathway will belong to the mutation group (green line). On the other hand, patients without a mutation in ‘Cell cycle’ genes will belong to the
mutation free group (red line). b ‘Her2’ subtype and ‘Oocyte meiosis’ pathway are selected, ‘Her2’ patients having at least one mutation in ‘Oocyte
meiosis’ genes are depicted as green line, and the rest ‘Her2’ patients are depicted as red line. P-value by the logrank test is provided for the
comparison of two groups, and all breast cancer patients are depicted as blue line for the convenience
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After loading a pathway, the user can explore multi-omics
data on the ‘Cell cycle’ pathway of ‘Basal’ subtype patients.
Figure 3a shows a pathway level view of gene expression,
mutation and copy number variation. By highlight func-
tion, user can locate genes with the specified condition.
The highlighted genes are mutation free, copy number
loss or deletion enriched but over-expressed compared to
normal pool data. Individual multi-omics data is obtained
by clicking each entry and Fig. 3b shows the multi-omics
data of CCNA1, CCNA2. Because mutation effects are
excluded, it would be interesting to see if there exist reg-
ulators that promoted the transcription of CCNA1 and
CCNA2. With ‘TF regulation’ checked, TF-TG correlation
coefficients are provided and then user can get the TFs
targeting CCNA1, CCNA2 and see that the correlation
coefficient between FOXP3 and CCNA2 is much differ-
ent in normal samples (0.58) and tumor samples (0.16).
Since p-value is over 0.05, correlation coefficient in ‘Basal’
subtype samples (-0.07) is shaded. Although we could
not identify the responsible genes that promoted tran-
scription of CCNA1 and CCNA2, we found that positive
correlation between FOXP3 as TF and CCNA2 as TG is
disrupted in tumor samples.
Conclusions
BRCA-Pathway helps researchers navigate multi-omics
data towards potentially important genes, regulators, and
discover complex patterns involving mutations, CNV, and
gene expression data of various patient groups in the bio-
logical pathway context. In addition, mutually exclusive
genomic alteration patterns in a specific pathway can be
generated. BRCA-Pathway can provide an integrative per-
spective on the breast cancer omics data, which can help
researchers discover new insights on the biological mech-
anisms of breast cancer. In the future, BRCA-Pathway
could include other omics data sets such as miRNA
expression and DNA promoter methylation profiles to
support more extensive research. And besides breast can-
cer data of TCGA, other cancer dataset availability is also
needed.
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